Bristol-Myers Squibb unit becomes Lantheus Medical Imaging

There's a new but familiar face on the radiopharmaceutical scene: Lantheus Medical Imaging, the new corporate identity of the company formerly known as Bristol-Myers Squibb Medical Imaging.

Lantheus today announced its new name and corporate look, operating as a standalone company for the first time since the firm's original inception as New England Nuclear in 1956. Lantheus was created by corporate owner Avista Capital Partners, the New York City investment firm that bought Bristol-Myers Squibb's medical imaging division in January for $525 million.

Lantheus will remain based in North Billerica, MA, and will continue to manufacture and market nuclear and ultrasound cardiovascular imaging products, including its flagship product, the Cardiolite technetium sestamibi-based SPECT radiopharmaceutical for heart perfusion studies. Other Lantheus products include the ultrasound contrast agent Definity and the TechneLite radiopharmaceutical.

The Lantheus executive team will be led by Don Kiepert as president and CEO. Kiepert was brought on board to lead the division following the Avista purchase, and before joining the company was the founder, chairman, president, and CEO of biopharmaceutical firm Point Therapeutics.

Lantheus also unveiled other management appointments. Phillip Lockwood has been named as vice president, human resources, after previously serving in the same post at Indevus Pharmaceuticals. The company's vice president and general counsel is Michael Duffy, who previously served as senior vice president and general counsel at Point Therapeutics.

Lantheus also promoted David Mann from vice president of sales to vice president, sales and marketing. Peter Card has been named as vice president, strategy and business development, while William Dawes takes the post of vice president, manufacturing and supply chain. Scott Edwards is vice president, global R&D, while Cyrille Villeneuve has become general manager for Canada, Latin America, and the Pacific Rim.

By Wayne Forrest staff writer
March 18, 2008

Related Reading

BMS posts last financials for medical imaging business, February 1, 2008

Avista completes Bristol-Myers Squibb buy, January 10, 2008

Bristol-Myers Squibb finds buyer for imaging unit, December 17, 2007

Bristol-Myers Squibb to divest imaging unit, including Cardiolite radiopharmaceutical, December 5, 2007

Bristol breast cancer drug aims at sickest women, October 16, 2007

Copyright © 2008

Page 1 of 593
Next Page